+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The effects of platelet activating factor acether on the cardiovascular system and their inhibition by a new highly specific platelet activating factor acether receptor antagonist bn 52021



The effects of platelet activating factor acether on the cardiovascular system and their inhibition by a new highly specific platelet activating factor acether receptor antagonist bn 52021



Pharmacological Research Communications 18(8): 717-738



BN 52021, a new specific PAF-acether receptor antagonist, was evaluated on several cardiovascular models. BN 52021 antagonized PAF-acether-induced extravasation in rats. Inhibition of the hypotensive action of PAF-acether was obtained by administration of the antagonist, given preventively or curatively. In isolated guinea-pig hearts, BN 52021 inhibited the vasoconstriction induced by PAF-acether whereas a small inhibition was observed with papaverine. On the other hand, phosphodiesterase inhibitors were very effective against coronary vasoconstriction induced by vasopressin while BN 52021 was without effect. PAF-acether increased the tonus of rat isolated portal vein; this effect was inhibited by BN 52021, without any reduction in basal myogenic activity. In this model Ca2+ antagonists (D 600, diltiazem) showed a small inhibitory effect but they strongly reduced basal myogenic activity. Neither PAF-acether nor BN 52021 modified phenylephrine-induced contraction of the isolated rabbit aorta with or without endothelium demonstrating that endothelium-dependent relaxing factor is not related to PAF-acether. Our results suggest that BN 52021 specifically block the cardiovascular effects of PAF-acether. This agent may thus ben an useful tool for a better understanding of the role of PAF-acether in hemodynamic changes involved in anaphylaxis or shock.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 006666498

Download citation: RISBibTeXText


Related references

The effects of paf acether platelet activating factor on the cardiovascular system and their inhibition by a new highly specific receptor antagonist bn 52021. Prostaglandins: 710, 1985

Proof of the involvement of paf acether platelet activating factor in pulmonary complex immune systems using a specific paf acether platelet activating factor receptor antagonist bn 52021. International Journal of Immunopharmacology 7(3): 385, 1985

The effects of paf acether platelet activating factor on the cardiovascular system and their inhibition by a new highly specific receptor antagonist bn 52021 2. hypotensive shock in the normal anesthetized rat comparison with the effects of salbutamol a beta 2 agonist. International Journal of Immunopharmacology 7(3): 385, 1985

The effects of paf acether platelet activating factor on the cardiovascular system and their inhibition by a new highly specific receptor antagonist bn 52021 1. vasospasm in isolated guinea pig heart and contraction of isolated rat portal vein. International Journal of Immunopharmacology 7(3): 385, 1985

Proof of the involvement of platelet activating factor (paf-acether) in pulmonary complex immune systems using a specific paf-acether receptor antagonist: BN 52021. Progress in Lipid Research 25(1-4): 277-288, 1986

Effects of platelet-activating factor on electrophysiology of isolated retinas and their inhibition by BN 52021, a specific PAF-acether receptor antagonist. Immunopharmacology 13(3): 189-194, 1987

Specific inhibition of paf acether induced platelet activation by bn 52021 and comparison with the platelet activating factor acether inhibitors kadsurenone and cv 3988. European Journal of Pharmacology 123(2): 197-206, 1986

Down regulation of beta 2 adrenergic receptors by paf acether platelet activating factor and its inhibition by the paf acether antagonist bn 52021. Prostaglandins 30(4): 721, 1985

Effect of BN 52021, a specific antagonist of platelet activating factor (PAF-acether), on calcium movements and phosphatidic acid production induced by PAF-acether in human platelets. Thrombosis Research 45(4): 299-309, 1987

In vivo inhibition of plasma protein leakage and endotoxin induced mortality in the rat by a specific paf acether platelet activating factor receptor antagonist bn 52021. Prostaglandins 30(4): 716, 1985

Inhibition of transmembrane movement and metabolism of platelet activating factor (PAF-acether) by a specific antagonist, BN 52021. Biochemical and Biophysical Research Communications 132(2): 460-466, 1985

Inhibition of antigen induced lung anaphylaxis in the guinea pig by bn 52021 a new specific platelet activating factor acether receptor antagonist isolated from ginkgo biloba. Agents & Actions 17(3-4): 371-372, 1986

The effects of PAF-acether on the cardiovascular system and their inhibition by a new highly specific PAF-acether receptor antagonist BN 52021. Pharmacological Research Communications 18(8): 717-737, 1986

Inhibition of human lymphocyte proliferation and interleukin 2 production by platelet activating factor (PAF-acether): reversal by a specific antagonist, BN 52021. Biochemical and Biophysical Research Communications 142(3): 754-760, 1987

Paf acether platelet activating factor induced cell activation studied on platelet and mast cell with fluorescent probes specific inhibition by a new antagonist bn 52021. Prostaglandins 30(4): 700, 1985